Christina Rossi - Nov 3, 2022 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role: CHIEF OPERATING OFFICER
Signature: /s/ Ariel Hurley, Attorney-in-Fact
Stock symbol: BPMC
Transactions as of: Nov 3, 2022
Transactions value $: -$24,113
Form type: 4
Date filed: 11/7/2022, 03:08 PM
Previous filing: Jun 17, 2022
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BPMC	Common Stock	Sale	-$24.1K	-533	-1.21%	$45.24	43.4K	Nov 3, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $45.11 to $45.24 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $45.11 to $45.24 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.